U.S. Food and Drug Administration (FDA)
Is Eloralintide legal in United States?
Not approvedInvestigational; Eli Lilly is running Phase 3 obesity trials and nothing is approved or filed
Not approved as a medicine here.
Eloralintide (Eli Lilly code LY3841136) is an investigational amylin-pathway medicine. Lilly's June 2026 quarterly filing reports that Phase 3 trials started for obesity add-on use, obstructive sleep apnea and osteoarthritis pain, and the ClinicalTrials.gov record for the Phase 3 obesity study without type 2 diabetes shows it recruiting. No marketing application has been reported, so it has no FDA approval and any sale outside a trial would be of an unapproved drug.
Last verified 2026-09-29 · how we verify
Eloralintide elsewhere
Sources (3)
- 01A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight Without Type 2 Diabetes, NCT07321886U.S. National Library of Medicine (ClinicalTrials.gov) · 2026-09 · accessed 2026-09-29
- 02Eli Lilly and Company Form 10-Q for the quarter ended 30 June 2026Eli Lilly and Company (SEC filing) · 2026-08-05 · accessed 2026-09-29
- 03Development & Approval Process | DrugsU.S. Food and Drug Administration · 2022-08-08 · accessed 2026-09-29